Evaluation of new anti-infective drugs for the treatment of osteomyelitis in adults

J. T. Mader, C. Norden, J. D. Nelson, G. B. Calandra

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Cases of osteomyelitis can be divided into four categories: acute hematogenous, vertebral, secondary to a contiguous focus of infection without vascular disease, and secondary to a contiguous focus of infection with vascular disease. Each category may be further divided into acute and chronic forms. Clinical symptoms persisting for ≥10 days correlate roughly with the development of necrotic bone and chronic osteomyelitis. Patients enrolled in clinical trials should generally be ≥12 years of age. Prior antimicrobial treatment does not exclude patients if the culture of a bone sample obtained at the time of enrollment yields pathogenic bacteria. Randomized, double- blind, active-control comparative studies are encouraged. Clinical outcome should be assessed during therapy and within 5-9 days, 4-6 weeks, and 11-13 months after completion of therapy. In the final assessment, clinical appraisal is paramount.

Original languageEnglish (US)
JournalClinical Infectious Diseases
Volume15
Issue numberSUPPL. 1
StatePublished - 1992

Fingerprint

Osteomyelitis
Vascular Diseases
Pharmaceutical Preparations
Bone Development
Infection
Therapeutics
Clinical Trials
Bacteria
Bone and Bones

ASJC Scopus subject areas

  • Immunology

Cite this

Evaluation of new anti-infective drugs for the treatment of osteomyelitis in adults. / Mader, J. T.; Norden, C.; Nelson, J. D.; Calandra, G. B.

In: Clinical Infectious Diseases, Vol. 15, No. SUPPL. 1, 1992.

Research output: Contribution to journalArticle

@article{19c8aa3167064f3b8791ac859f88d0c7,
title = "Evaluation of new anti-infective drugs for the treatment of osteomyelitis in adults",
abstract = "Cases of osteomyelitis can be divided into four categories: acute hematogenous, vertebral, secondary to a contiguous focus of infection without vascular disease, and secondary to a contiguous focus of infection with vascular disease. Each category may be further divided into acute and chronic forms. Clinical symptoms persisting for ≥10 days correlate roughly with the development of necrotic bone and chronic osteomyelitis. Patients enrolled in clinical trials should generally be ≥12 years of age. Prior antimicrobial treatment does not exclude patients if the culture of a bone sample obtained at the time of enrollment yields pathogenic bacteria. Randomized, double- blind, active-control comparative studies are encouraged. Clinical outcome should be assessed during therapy and within 5-9 days, 4-6 weeks, and 11-13 months after completion of therapy. In the final assessment, clinical appraisal is paramount.",
author = "Mader, {J. T.} and C. Norden and Nelson, {J. D.} and Calandra, {G. B.}",
year = "1992",
language = "English (US)",
volume = "15",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Evaluation of new anti-infective drugs for the treatment of osteomyelitis in adults

AU - Mader, J. T.

AU - Norden, C.

AU - Nelson, J. D.

AU - Calandra, G. B.

PY - 1992

Y1 - 1992

N2 - Cases of osteomyelitis can be divided into four categories: acute hematogenous, vertebral, secondary to a contiguous focus of infection without vascular disease, and secondary to a contiguous focus of infection with vascular disease. Each category may be further divided into acute and chronic forms. Clinical symptoms persisting for ≥10 days correlate roughly with the development of necrotic bone and chronic osteomyelitis. Patients enrolled in clinical trials should generally be ≥12 years of age. Prior antimicrobial treatment does not exclude patients if the culture of a bone sample obtained at the time of enrollment yields pathogenic bacteria. Randomized, double- blind, active-control comparative studies are encouraged. Clinical outcome should be assessed during therapy and within 5-9 days, 4-6 weeks, and 11-13 months after completion of therapy. In the final assessment, clinical appraisal is paramount.

AB - Cases of osteomyelitis can be divided into four categories: acute hematogenous, vertebral, secondary to a contiguous focus of infection without vascular disease, and secondary to a contiguous focus of infection with vascular disease. Each category may be further divided into acute and chronic forms. Clinical symptoms persisting for ≥10 days correlate roughly with the development of necrotic bone and chronic osteomyelitis. Patients enrolled in clinical trials should generally be ≥12 years of age. Prior antimicrobial treatment does not exclude patients if the culture of a bone sample obtained at the time of enrollment yields pathogenic bacteria. Randomized, double- blind, active-control comparative studies are encouraged. Clinical outcome should be assessed during therapy and within 5-9 days, 4-6 weeks, and 11-13 months after completion of therapy. In the final assessment, clinical appraisal is paramount.

UR - http://www.scopus.com/inward/record.url?scp=0026488693&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026488693&partnerID=8YFLogxK

M3 - Article

C2 - 1477223

AN - SCOPUS:0026488693

VL - 15

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - SUPPL. 1

ER -